首页|期刊导航|肿瘤药学|卵巢癌复发治疗的研究进展

卵巢癌复发治疗的研究进展

LIU Shan WANG Jing LIU Lu OUYANG Peilin

肿瘤药学2019，Vol.9Issue(2)：189-192,4.

肿瘤药学2019，Vol.9Issue(2)：189-192,4.DOI:10.3969/j.issn.2095-1264.2019.02.03

卵巢癌复发治疗的研究进展

Research Progress of the Treatment of Recurrent Ovarian Cancer

LIU Shan ¹WANG Jing ²LIU Lu ¹OUYANG Peilin²

作者信息

1. University of South China, Hengyang, Hunan, 421001, China
2. Hunan Cancer Hospital / The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China
折叠

摘要

Abstract

Ovarian cancer is a common gynecological cancer. Its mortality and recurrence rate ranks the first in gynecological cancers. It has become a hotspot to research the treatments of recurrent ovarian cancer. A large number of clinical trials have investigated the treatments of recur-rent ovarian cancer such as secondary cytoreductive surgery, chemotherapy and targeted medicine. In particular, breakthroughs have been made in targeted therapies like bevacizumab and PARP inhibitors. A variety of PARP inhibitor medicines have been approved for clinic, providing more treatment choices for recurrent ovarian cancer. This article mainly reviewed the research progress of the treatments of recurrent ovarian cancer.

关键词

复发性卵巢癌/二次减灭术/靶向药物/贝伐珠单抗/PARP酶抑制剂

Key words

Recurrent ovarian cancer/Secondary cytoreductive surgery/Targeted medicine/Bevacizumab/PARP inhibitors

分类

医药卫生

引用本文复制引用

LIU Shan,WANG Jing,LIU Lu,OUYANG Peilin..卵巢癌复发治疗的研究进展[J].肿瘤药学,2019,9(2):189-192,4.

基金项目

湖南省自然科学基金(2018JJ6027). （2018JJ6027）

肿瘤药学

OACSTPCD

ISSN：2095-1264

访问量2

下载量0

段落导航